Peer-Reviewed Publication
Bioorg Chem2026;173109609.June 5, 2026Journal Article
The Multi-Faceted Landscape of TEAD Inhibition: a 2017-2025 Patent and Literature Review.
Violet Yijang Chen1, Jianfei Wan2, Xiao Ding3, Feng Ren4, Alex Zhavoronkov5
1FLM4, ATMD-4, TSMC, Global R&D Center (F12P8), 168, Kehuan Rd., Hsinchu Science Park, Hsinchu 308-001, Taiwan; Insilico Medicine Taiwan Ltd., Suite 1303, No 333, Section 1, Keelung Rd, Xinyi Dist, Taipei, Taiwan. Electronic address: yjchendd@tsmc.com.
2Insilico Medicine Shanghai Ltd., Suite 902, Tower C, Changtai Plaza, 2889 Jinke Road Pudong New Area, Shanghai 201203, China. Electronic address: jianfei.wan@insilico.ai.
3Insilico Medicine Shanghai Ltd., Suite 902, Tower C, Changtai Plaza, 2889 Jinke Road Pudong New Area, Shanghai 201203, China. Electronic address: xiao.ding@insilico.ai.
4Insilico Medicine Shanghai Ltd., Suite 902, Tower C, Changtai Plaza, 2889 Jinke Road Pudong New Area, Shanghai 201203, China. Electronic address: feng.ren@insilico.ai.
5Insilico Medicine Shanghai Ltd; Insilico Medicine AI Limited, Suite 902, Tower C, Changtai Plaza, 2889 Jinke Road Pudong New Area, Shanghai 201203, China; Insilico Medicine Shanghai Ltd; Insilico Medicine AI Limited, Masdar City, Abu Dhabi 145748, United Arab Emirates. Electronic address: alex@insilicomedicine.com.
Abstract
TEAD (Transcriptional Enhanced Associated Domain) is a family of transcription factors whose involvement in the Hippo pathway plays a crucial role in cellular homeostasis and preventing tumorigenesis. Aberrant YAP/TAZ-TEAD activation is a key driver of various cancers, making it an attractive and therapeutically relevant target. Current challenges include nephrotoxicity as a potential on-target ef…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans